For example, inclisiran can inhibit the synthesis of protein convertase subtilisin-kexin type 9 (PCSK9), thus lowering the level of low-density lipoprotein (LDL) and helping people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, or heterozygous familial hypercholesterolemia (HeFH). The gene discussed is PCSK9; the disease is atherosclerosis.